Transversal sero-epidemiological study of Bordetella pertussis in Tehran, Iran

Gaelle Noel, Farzad Badmasti, Vajihe S Nikbin, Seyed M Zahraei, Yoann Madec, David Tavel, Mohand Aït-Ahmed, Nicole Guiso, Fereshteh Shahcheraghi, Fabien Taieb, Gaelle Noel, Farzad Badmasti, Vajihe S Nikbin, Seyed M Zahraei, Yoann Madec, David Tavel, Mohand Aït-Ahmed, Nicole Guiso, Fereshteh Shahcheraghi, Fabien Taieb

Abstract

Objectives: Pertussis remains endemic despite high vaccine coverage in infants and toddlers. Pertussis vaccines confer protection but immunity wanes overtime and boosters are needed in a lifetime. Iran, eligible for the Expanded Program on Immunization that includes the primary immunization, implemented two additional booster doses using a whole-cell vaccine (wPV) at 18 months-old and about 6 years-old. Duration of protection induced by the wPVs currently in use and their impact as pre-school booster are not well documented. This study aimed at assessing vaccination compliance and at estimating the duration of protection conferred by vaccination with wPV in children aged < 15 years in Tehran, Iran.

Methods: Detailed information on vaccination history and capillary blood samples were obtained from 1047 children aged 3-15 years who completed the 3 doses-primary pertussis immunization, in Tehran. Anti-pertussis toxin IgG levels were quantified by ELISA.

Results: Compliance was very high with 93.3% of children who received the three primary and 1st booster doses in a timely manner. Timeliness of the 2nd booster was lower (63.3%). Rate of seropositive samples continuously and significantly increased from 1-2 to 5-6 years after 1st booster attaining 30.4% of children exhibiting serological sign of recent contact with B. pertussis. Second booster dating back 1 or 2 years was associated with high antibody titers, which significantly decreased within 3 years from injection. Among children who received 2nd booster injection more than 2 years before serum analysis, seroprevalence of pertussis infection was 8.4% and seropositivity rate was higher from the 10 years-old group.

Conclusion: Seropositivity in children aged 6-7 years with no 2nd booster supports the need for a vaccination at that age. Adolescent booster may also be considered.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Compliance with Iranian pertussis immunization…
Fig 1. Compliance with Iranian pertussis immunization schedule.
Numbers (n) and proportions (%) of children who received early (light grey), on time (white) or late (dark grey) their pertussis vaccine dose as compared to Iranian recommendations are shown for each injection. Respect to intervals in between 1st and 2nd, and 2nd and 3rd are shown with respect to compliance with 1st and 2nd dose, respectively. Days (d); weeks (w); years (y).
Fig 2. Distribution of anti-PT IgG levels…
Fig 2. Distribution of anti-PT IgG levels by timespan since 1st booster among individuals who received 4 injections.
Timespans were categorized by year.
Fig 3. Distribution of anti-PT IgG levels…
Fig 3. Distribution of anti-PT IgG levels by age groups among fully vaccinated individuals since >2 years.

References

    1. WHO. Pertussis vaccines: WHO position paper Wkly Epidemiol Rec 2015;. August 2015;90:433–58.
    1. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. The Lancet Infectious Diseases. 2017;17(9):974–80. 10.1016/S1473-3099(17)30390-0
    1. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. The Lancet Infectious Diseases. 2011;11(7):557–70. 10.1016/S1473-3099(11)70007-X
    1. Guiso N, de La Rocque F, Njamkepo E, Lécuyer A, Levy C, Romain O, et al. Pertussis Surveillance in Private Pediatric Practices, France, 2002–2006. Emerging Infectious Disease journal. 2008;14(7):1159.
    1. Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, Tischer A, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and infection. 2005;133(1):159–71. 10.1017/s0950268804003012
    1. Grimprel E, Bégué P, Anjak I, Njamkepo E, François P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clinical and Diagnostic Laboratory Immunology. 1996;3(1):93–7.
    1. Guiso N, Taieb F. Pertussis in Low and Medium Income Countries: A Pragmatic Approach. Advances in Experimental Medicine and Biology. 2019(0065–2598 (Print)).
    1. WHO, editor. Immunological basis for immunization: Pertussis (2017 update)November 2017.
    1. von Koenig CHW, Guiso N. Global burden of pertussis: signs of hope but need for accurate data. The Lancet Infectious Diseases. 2017;17(9):889–90. 10.1016/S1473-3099(17)30357-2
    1. Moradi-Lakeh M, Esteghamati A. National Immunization Program in Iran: whys and why nots. Human vaccines & immunotherapeutics. 2013;9(1):112–4.
    1. Pourakbari B, Moradi B, Mirzaee F, Mahmoudi S, Teymuri M, Mamishi S. Seroprevalence of antibodies to diphtheria, tetanus and pertussis among healthy adolescents and adults in Iran. Roumanian archives of microbiology and immunology. 2013;72(4):250–4.
    1. Shamsizadeh A, Nikfar R, Yusefi H, Abbasi-Montazeri E, Cheraghian B. Seroprevalence of pertussis antibodies in 6-17-year-old students in Ahvaz, south-west Islamic Republic of Iran. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2014;20(10):623–6.
    1. WHO. Laboratory manual for the diagnosis of whooping cough caused by Bordetella pertussis/Bordetella parapertussis. 2014
    1. WHO. Global and Regional Immunization Profile. WHO vaccine-preventable disease monitoring system. 2018.
    1. Sadeghpour Heravi F, Nikbin VS, Nakhost Lotfi M, Badiri P, Jannesar Ahmadi N, Zahraei SM, et al. Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran. European Journal of Clinical Microbiology & Infectious Diseases. 2018;37(10):1893–900.
    1. Sedaghat M, Nakhost Lotfi M, Talebi M, Saifi M, Pourshafie MR. Status of Pertussis in Iran. Jundishapur Journal of Microbiology. 2014;7(11):e12421 10.5812/jjm.12421
    1. Guiso N, Berbers G, Fry NK, He Q, Riffelmann M, Wirsing von König CH, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2011;30(3):307–12.
    1. Kurova N, Timofeeva E, Guiso N, Macina D. A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia. Vaccine. 2018.
    1. Barkoff A-M, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathogens and Disease. 2015;73(7):ftv050–ftv. 10.1093/femspd/ftv050
    1. Scott S, van der Sande M, Faye-Joof T, Mendy M, Sanneh B, Barry Jallow F, et al. Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates. The Pediatric infectious disease journal. 2015;34(4):333–8. 10.1097/INF.0000000000000576
    1. Arefi Z, Kazemi Z, Shaahmadi Z, Mahmoudi S, Shaahmadi F. The Trend of the Extended Program of Immunization (EPI) in Iran from the Beginning (1984) to 2013. International Journal of Pediatrics. 2015;3(4.1):717–23.
    1. Riffelmann M, Thiel K, Schmetz J, Wirsing von Koenig CH. Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis. Journal of Clinical Microbiology. 2010;48(12):4459–63. 10.1128/JCM.01371-10
    1. Wirsing von Konig CH, Gounis D, Laukamp S, Bogaerts H, Schmitt HJ. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis. 1999;18(5):341–5. 10.1007/pl00015016
    1. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, Elvers LH, Berbers GA, van Der Zee A, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. Journal of clinical microbiology. 2000;38(2):800–6. 10.1128/JCM.38.2.800-806.2000
    1. WHO. WHO vaccine-preventable diseases: monitoring system. 2018 global summary 2018 [updated 22-Oct-2018. Available from: .
    1. Sedighi I, Karimi A, Amanati A. Old Disease and New Challenges: Major Obstacles of Current Strategies in the Prevention of Pertussis. Iran J Pediatr. 2016;26(4):e5514 10.5812/ijp.5514
    1. Rejali M, Mohammadbeigi A, Mokhtari M, Zahraei SM, Eshrati B. Timing and delay in children vaccination; evaluation of expanded program of immunization in outskirt of Iranian cities. JRHS. 2015;15(1):54–8.
    1. Poorolajal J, Khazaei S, Kousehlou Z, Bathaei S, Zahiri A. Delayed Vaccination and Related Predictors among Infants. Iranian journal of public health. 2012;41(10):65–71.
    1. Tauil MdC, Sato APS, Waldman EA. Factors associated with incomplete or delayed vaccination across countries: A systematic review. Vaccine. 2016;34(24):2635–43. 10.1016/j.vaccine.2016.04.016
    1. Khan J, Shil A, Prakash R. Exploring the spatial heterogeneity in different doses of vaccination coverage in India. PloS one. 2018;13(11):e0207209–e. 10.1371/journal.pone.0207209
    1. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21(17):2003–14.
    1. Guiso N, Levy C, Romain O, Guillot S, Werner A, Rondeau MC, et al. Whooping cough surveillance in France in pediatric private practice in 2006–2015. Vaccine. 2017;35(45):6083–8. 10.1016/j.vaccine.2017.09.072
    1. Berbers GAM, van de Wetering MSE, van Gageldonk PGM, Schellekens JFP, Versteegh FGA, Teunis PFM. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens. Vaccine. 2013;31(36):3732–8. 10.1016/j.vaccine.2013.05.073
    1. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine. New England Journal of Medicine. 1996;334(6):349–56. 10.1056/NEJM199602083340602
    1. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SGF. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. The Journal of Pediatrics. 1998;132(6):983–8. 10.1016/s0022-3476(98)70395-6
    1. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16(20):1907–16. 10.1016/s0264-410x(98)00227-8
    1. Edwards KM, Berbers GAM. Immune Responses to Pertussis Vaccines and Disease. The Journal of Infectious Diseases. 2014;209(suppl_1):S10–S5.
    1. Campbell H, Gupta S, Dolan GP, Kapadia SJ, Kumar Singh A, Andrews N, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. Journal of Medical Microbiology. 2018;67(10):1426–56. 10.1099/jmm.0.000829
    1. Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC medicine. 2015;13:146–146. 10.1186/s12916-015-0382-8

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe